Brain-derived neurotrophic factor levels in newly diagnosed patients with bipolar disorder, their unaffected first-degree relatives and healthy controls

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Nanna Aagaard Petersen
  • Marc Ostergaard Nielsen
  • Klara Coello
  • Sharleny Stanislaus
  • Sigurd Melbye
  • Hanne Lie Kjærstad
  • Kimie Stefanie Ormstrup Sletved
  • Roger S. McIntyre
  • Ruth Frikke-Smith
  • Vinberg, Maj
  • Kessing, Lars Vedel

Background Brain-derived neurotrophic factor (BDNF), which facilitates neuroplasticity and synaptogenesis, may be decreased in bipolar disorder, but has not been systematically investigated in people with newly diagnosed bipolar disorder and unaffected first-degree relatives. Aims To compare BDNF levels in patients with newly diagnosed bipolar disorder, their unaffected first-degree relatives and healthy controls. Method The study investigated plasma BDNF levels in patients (n = 371) with newly diagnosed bipolar disorder, their unaffected first-degree relatives (n = 98) and healthy controls (n = 200) using enzyme-linked immunosorbent assay. We further investigated associations between BDNF levels and illness-related variables and medication status. Results BDNF levels were found to be 22.0% (95% CI 1.107-1.343) higher in patients with bipolar disorder compared with healthy controls (P < 0.001) and 15.6% higher in unaffected first-degree relatives compared with healthy controls (95% CI 1.007-1.327, P = 0.04), when adjusting for age and gender. Further, BDNF levels were positively associated with duration of illness at a trend level (P = 0.05), age (P = 0.001) and use of anti-epileptic medication (P = 0.05). Conclusions These findings suggest that BDNF levels are not decreased in the early stages of bipolar disorder and in unaffected first-degree relatives contrasting with prior findings during later stages of the illness.

OriginalsprogEngelsk
Artikelnummere55
TidsskriftBJPsych Open
Vol/bind7
Udgave nummer2
ISSN2056-4724
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
L.V.K. has within the last 3 years been a consultant for Lundbeck and Sunovion. M.V. has within the last 3 years been a consultant for Lundbeck, JanssenCilag and Sunovion. R.S.M. reports research or grants from private industries or non-profit funds: Stanley Medical Research Institute, CIHR/GACD/ National Natural Science Foundation of China; and consultation/speaker fees from: Lundbeck, Janssen, Shire, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, Minerva. R.F.-S. reports consultancy for Novo Nordisk (2019). The remaining authors declare no conflicts of interest.

Funding Information:
The study was funded by grants from the Mental Health Services, Capital Region of Denmark, The Danish Council for Independent Research, Medical Sciences (DFF – 4183-00570),Weimans Fund, Markedmodningsfonden (the Market Development Fund, (2015-310), Gangstedfonden (A29594), Helsefonden (16-B-0063), Innovation Fund Denmark (the Innovation Fund, Denmark, 5164-00001B), Copenhagen Center for Health Technology (CACHET), EU H2020 ITN (EU project 722561), Augustinusfonden (16-0083), Lundbeck foundation (R215-2015-4121).

Publisher Copyright:
Copyright © The Author(s), 2021. Published by Cambridge University Press on behalf of the Royal College of Psychiatrists.

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 273653382